Home   >  

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Apoptosis Pathway

Chemical Structure Cat. No. Product Name CAS No.
YM-155 hydrochloride Chemical Structure
BCP35549 YM-155 hydrochloride 355406-09-6
YM155 is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM.
RIPK1-IN-4 Chemical Structure
BCP35149 RIPK1-IN-4 1481641-08-0
RIPK1-IN-4 is a potent and selective type II kinase inhibitor of receptor interacting protein 1 (RIP1) kinase and binds to a DLG-out inactive form of RIP1 with an IC50s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase.
MARK4 inhibitor 1 Chemical Structure
BCP34908 MARK4 inhibitor 1 2271081-58-2
MARK4 inhibitor 1 is a potent microtubule affinity-regulating kinase 4 (MARK4) inhibitor, with an IC50 of 1.54 μM.
Kinetin riboside Chemical Structure
BCP34390 Kinetin riboside 4338-47-0
Kinetin Riboside used as an anticancer and antiviral agent.
Ibandronate sodium monohydrate Chemical Structure
BCP34266 Ibandronate sodium monohydrate 138926-19-9
Ibandronate Sodium Monohydrate is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
Nivalenol Chemical Structure
BCP34262 Nivalenol 23282-20-4
Nivalenol is a kind of type-B trichothecene mycotoxin, could be used as standard solution.
MYCi975 Chemical Structure
BCP34062 MYCi975 2289691-01-4
MYCi975 is an orally active MYC inhibitor, which disrupts MYC/MAX interaction, promotes MYC T58 phosphorylation and MYC degradation, and impairs MYC driven gene expression.
MYCi361 Chemical Structure
BCP34061 MYCi361 2289690-31-7
MYCi361 is a MYC inhibitor with the Kd of 3.2 μM for binding to MYC.
Donafenib Chemical Structure
BCP34023 Donafenib 1130115-44-4
Donafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib is under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC).
BMS-1001 Chemical Structure
BCP33668 BMS-1001 2113650-03-4
BMS-1001 is a potent PD-1/PD-L1 interaction inhibitor.
123下一页末页共 245 条记录 1 / 25 页 
0086-15971444841